Bendamustine in Chinese Participants With Non-Hodgkin Lymphoma
- Study Title
- Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
- Teva Identifier
- C18083/3076
- ClinicalTrials.gov Identifier
- NCT01596621
- Study Status
- Completed
- Trial Condition(s)
- Non-Hodgkin Lymphoma
- Interventions
- Drug: Bendamustine hydrochloride
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- August 6, 2012 - April 28, 2017
- Phase
- Phase 3